NEW YORK (Reuters)—President Donald Trump’s reversals in the past week on maintaining Obamacare subsidies to insurers are sowing new confusion over what kind of health insurance will be available to consumers, and at what price, when enrollment for 2018 begins in two weeks. Trump said last week his administration would stop paying billions of dollars…
Search results for: hospital
Biosimilar Infliximab Appears Safe, Effective in Pediatric IBD
NEW YORK (Reuters Health)—A biosimilar version of infliximab appears as effective as the original for treating pediatric inflammatory bowel disease (PIBD), and less costly, new research shows. “These baseline data have now enabled us to confidently switch patients from originator to biosimilar, adopting the same prospective methodology to monitor effectiveness, safety and cost,” Dr. Lisa…
Some Middle-Class Americans Worry Trump Health Subsidies Cut Will Hurt
PHILADELPHIA (Reuters)—Tom Westerman voted for Donald Trump in last year’s election but says he might not do so again after the president cut off billions of dollars in Obamacare subsidies to health insurance companies. “It really upset me,” said Westerman, 63, a self-described “middle-class guy” with an annual household income of about $60,000 in the…
Rheumatologists Find Nailfold Capillaroscopy an Increasingly Useful Diagnostic Tool
Interest in viewing the nail capillaries dates to the late 17th century. Later research by Maurice Raynaud and others in the late 19th and early 20th century first established a direct link between the nailfold capillaries and certain medical conditions. Although underutilized in the past, with the advent of modern digital equipment and the validation…
Rheumatologist’s Passion for Gardening Keeps Plants, Patients Healthy
Deborah Dyett Desir, MD, vividly remembers her first day as an undergraduate student at Harvard University, Boston. When her parents helped her move into the dorm, her mother, Betty, handed her a beautiful begonia. “My response was, ‘What on earth am I going to do with this plant?’” she says, recalling how she examined the…
U.S. Senators Reach Bipartisan Deal on Obamacare Backed by Trump
WASHINGTON (Reuters)—On Tuesday, two U.S. senators announced a bipartisan breakthrough to shore up Obamacare for two years by reviving federal subsidies for health insurers that President Donald Trump planned to scrap, and the president voiced support for the plan. The agreement worked out by Sen. Lamar Alexander (R-Tenn.) and Sen. Patty Murray (D-Wash.) would meet…
Rheumatology Case Report: Monoarticular Arthritis in Pregnancy
Limited data exist on the clinical presentation of Muckle–Wells syndrome (MWS) during pregnancy. The purpose of this case report is to highlight the diagnosis of MWS in a pregnant woman. Many rheumatic diseases affect women of childbearing age, and their management during pregnancy can be challenging. Case A 33-year-old, 18-weeks’ pregnant woman was hospitalized for…
Fulbright Scholar Researches Physical Activity in Swedish Children with Juvenile Idiopathic Arthritis
A stroll through downtown Stockholm presents a quintessential picture of an active community, with most people biking or walking as their preferred mode of travel. Yet children in Sweden who live with juvenile idiopathic arthritis (JIA)—currently estimated at around 64 of every 100,000—don’t always engage in this active lifestyle.1 Maura Daly Iversen, PT, DPT, SD,…
Pain Treatments Move Closer to U.S. Market
Two pain treatments, extended-release injectable suspension triamcinolone acetonide (Zilretta) and meloxicam, have seen movement at the U.S. Food and Drug Administration (FDA). In October, the agency approved Zilretta to treat osteoarthritis (OA) knee pain and accepted a new drug application for meloxicam to treat pain. FDA Approves Zilretta On Oct. 6, the FDA approved extended-release,…
Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab
FDA Approves Adalimumab-adbm On Aug. 29, the FDA approved Cyltezo (adalimumab-adbm), a biosimilar to Humira (adalimumab).1 Cyltezo was approved as a prefilled syringe to treat multiple chronic inflammatory diseases, including moderate to severe active RA, active psoriatic arthritis and ankylosing spondylitis, and moderate to severe plaque psoriasis. The treatment has also been approved for moderate…
- « Previous Page
- 1
- …
- 170
- 171
- 172
- 173
- 174
- …
- 323
- Next Page »